Dec04Mon

Member News from Almac Group

Almac Discovery publishes USP7 inhibitors from UbiPlexTM Platform

Craigavon, N.I., UK, 4 December 2017 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, has today published its findings on the discovery and characterisation of highly potent, selective and reversible inhibitors of ubiquitin-specific protease 7 (USP7) in the journal Nature Chemical Biology. Despite substantial efforts over nearly two decades, the development of validated deubiquitinase (DUB) inhibitors that exhibit drug like properties and a well-defined mechanism has proven particularly challenging—overall, Almac’s findings successfully demonstrate the tractability and druggability of DUBs, and provide important tools for additional target validation studies.

Read More

Nov30Thu

Member News from SmartInvest

Local Spark Creates Momentum for International Success, SmartInvest Ventures Welcomes New Partner

WILMINGTON, Delaware, November 29, 2017 – SmartInvest Ventures (“SmartInvest”), an international venture capital firm, announced today that Martin Hunt, joins the team as a general partner, along side Charles “Chuck” Kerrigan, Fred Hosaisy and managing general partner, Gerry Moan. With more than 25 years of experience in private equity, insurance, strategy consulting and investment banking with over $20 billion in M&A transactional experience, along with degrees from the Harvard Business School and Swarthmore College – where he was a McCabe scholar, Mr. Hunt brings both his expertise and local connections to SmartInvest’s newest geographical focus – Delaware.

Read More

Nov07Tue

Member News from ICON

ICON contributes to major European research study that aims to improve treatment for traumatic brain injury

Recommendations from the longitudinal observational research study will be presented today at the European Parliament  

Dublin, Ireland, 7 November 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has contributed to a complex pan-European traumatic brain injury (TBI) research study involving over 4,500 patients in 65 sites in 20 European countries. ICON provided site management and source data verification (SDV) services to the study, which was supported by the European Union and led by Professor Andrew Maas from the University Hospital Antwerp (Belgium) and Professor David Menon from the University of Cambridge (UK).  ICON’s Dr. Valérie Legrand, VP Project Management and a recognised expert in CNS, also provided clinical expertise as a member of the project’s Management Committee. The Lancet Neurology Commission on TBI is being launched at the European Parliament today and will set out clinical and research priorities and recommendations to address the varied challenges in TBI.

Read More

Nov01Wed

Member News from Almac

Almac Group Announces Acquisition of BioClin Laboratories
Significant global expansion of existing analytical services

 

Craigavon, N.I., 01 November 2017 – Almac Group, the global contract development and manufacturing organisation, today announced the acquisition of 100% shares of BioClin Laboratories, an independent and privately owned organisation based in Athlone, Ireland.

Established in 2002 and located in Garrycastle, just two hours away from Almac Group’s Headquarters in Northern Ireland, BioClin is internationally recognised for providing expert analytical services including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing and GLP bioanalysis. The company also boasts Ireland’s leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory.

Read More

Oct27Fri

Member News from ICON

ICON and the International Consortium for Health Outcomes Measurement unveil the world’s first global patient outcomes benchmarking platform

Dublin, Ireland, 27 October 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and the International Consortium for Health Outcomes Measurement (ICHOM), a non-profit organization with the mission of driving value based health care, shared the findings of a global patient outcomes benchmarking platform at this week’s ICHOM’s annual conference in Washington DC. The platform aims to catalyse physician driven learning and improvement of the outcomes that matter most to patients.

ICON and ICHOM first partnered to advance value-based healthcare through the launch of a global healthcare outcomes benchmarking pilot program called GLOBE in March 2016.

Read More